Anti-Human CD85j/LILRB1/ILT2 (BND-22) (HV631016) is a research-grade recombinant antibody targeting CD85. Produced in mammalian cells with native-like glycosylation.
Highlights
●Research Grade — For PK/PD studies, assay development, and ADA research.
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型
IgG2a, kappa
克隆号
BND-22
表达系统
Mammalian cells
靶标
LIR1, Immunoglobulin-like transcript 2, MIR7, CD85 antigen-like family member J, Monocyte/macrophage immunoglobulin-like receptor 7, ILT-2, Leukocyte immunoglobulin-like receptor subfamily B member 1, LIR-1, CD85j, ILT2, LILRB1, MIR-7, Leukocyte immunoglobulin-like receptor 1
内毒素水平
< 10 EU/mg
纯度
>95% purity as determined by SDS-PAGE.
纯化方式
Protein A/G purified from cell culture supernatant.
Accession号
Q8NHL6
状态
Liquid
保存溶液
0.01M PBS pH 7.4
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景
Leukocyte immunoglobulin-like receptor subfamily B member 1 (CD85j/LILRB1) is a ~70 kDa protein. Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis.
1. Shiroishi, M. et al. (2006) The Journal of biological chemistry 281, 10439-47. PMID: 16455647
